Studies measuring TF activity of EVs using a FXa generation assay
| Disease/treatment . | Sample . | Results . | Reference . |
|---|---|---|---|
| Pancreatic adenocarcinoma | PPP | Levels of TF activity was higher in patients with cancer with VTE than those without VTE, and were associated with metastatic disease and short survival | 111 |
| Ovarian cancer | PPP | No association between levels of EV TF activity and VTE in patients with cancer | 112 |
| Cancer | PPP | Levels of EV TF activity were increased in patients with cancer compared with patients without cancer who were severely ill and healthy controls. Levels of EV TF activity were associated with mortality | 113 |
| Lung cancer | PPP | No difference of levels of EV TF activity between patients with cancer with or without low–molecular weight heparin treatment | 114 |
| Lupus | PPP | No difference in levels of EV TF activity between patients with lupus anticoagulants with history of thrombosis and healthy controls | 115 |
| Hantavirus cardiopulmonary syndrome | Plasma | Levels of EV TF activity were increased in patients with HCPS compared with healthy controls | 116 |
| Multiple myeloma | PFP | Levels of EV TF activity were increased in patients with multiple myeloma compared with controls | 117 |
| Pancreatic and colorectal cancer | PPP | Two of 13 patients with pancreatic cancer had elevated levels of EV TF activity. No patient with colorectal cancer had elevated levels of EV TF activity | 118 |
| Hemorrhagic fever with renal syndrome | Plasma | Levels of EV TF activity were transiently increased during HFRS and patients with DIC showed higher levels of EV TF activity than patients without DIC | 119 |
| HIV | Levels of EV TF activity were associated with carotid artery plaque in patients with HIV | 120 | |
| Cancer | Plasma | No association between the levels of EV TF activity and VTE | 121 |
| Cancer | PPP | Levels of EV TF activity were increased in patients with cancer compared with healthy controls | 122 |
| COVID-19 | PPP | Levels of EV TF activity were increased in patients with COVID-19 compared with controls, and were associated with disease severity and mortality | 110 |
| COVID-19 | PFP | Levels of EV TF activity were increased in patients with severe COVID-19 and were associated with an increased thrombotic risk | 16 |
| COVID-19 and sepsis | PPP | Levels of EV TF activity were higher in ICU patients with COVID-19 than in patients with sepsis | 123 |
| Sepsis | PPP | Levels of EV TF activity were higher in patients with septic DIC than in healthy controls | 124 |
| Leukemia | PFP | Levels of EV TF activity were increased in patients with leukemia compared with controls | 125 |
| Prostate cancer | PPP | Levels of EV TF activity were increased in patients with cancer with DIC compared with patients with cancer without DIC | 126 |
| Lung cancer | PFP | Levels of EV TF activity were increased in patients with cancer compared with healthy controls. | 127 |
| COVID-19 | PFP | Levels of EV TF activity were higher in patients with COVID-19 than in healthy controls | 128 |
| COVID-19 | PFP | Levels of EV TF activity were higher in small EVs than in large EVs from patients with COVID-19 | 80 |
| Sepsis, pancreatic cancer, and COVID-19 | PFP and PPP | Levels of EV TF activity of small or large EVs were different depending on the disease | 129 |
| Sepsis | PPP | Levels of EV TF activity were increased in patients with sepsis with DIC compared with patients with sepsis without DIC. Levels of EV TF activity were associated with inflammatory markers and DIC score | 130 |
| Leukemia | PPP | Levels of EV TF activity were increased in patients with leukemia compared with controls, and were associated with risk of bleeding | 131 |
| Disease/treatment . | Sample . | Results . | Reference . |
|---|---|---|---|
| Pancreatic adenocarcinoma | PPP | Levels of TF activity was higher in patients with cancer with VTE than those without VTE, and were associated with metastatic disease and short survival | 111 |
| Ovarian cancer | PPP | No association between levels of EV TF activity and VTE in patients with cancer | 112 |
| Cancer | PPP | Levels of EV TF activity were increased in patients with cancer compared with patients without cancer who were severely ill and healthy controls. Levels of EV TF activity were associated with mortality | 113 |
| Lung cancer | PPP | No difference of levels of EV TF activity between patients with cancer with or without low–molecular weight heparin treatment | 114 |
| Lupus | PPP | No difference in levels of EV TF activity between patients with lupus anticoagulants with history of thrombosis and healthy controls | 115 |
| Hantavirus cardiopulmonary syndrome | Plasma | Levels of EV TF activity were increased in patients with HCPS compared with healthy controls | 116 |
| Multiple myeloma | PFP | Levels of EV TF activity were increased in patients with multiple myeloma compared with controls | 117 |
| Pancreatic and colorectal cancer | PPP | Two of 13 patients with pancreatic cancer had elevated levels of EV TF activity. No patient with colorectal cancer had elevated levels of EV TF activity | 118 |
| Hemorrhagic fever with renal syndrome | Plasma | Levels of EV TF activity were transiently increased during HFRS and patients with DIC showed higher levels of EV TF activity than patients without DIC | 119 |
| HIV | Levels of EV TF activity were associated with carotid artery plaque in patients with HIV | 120 | |
| Cancer | Plasma | No association between the levels of EV TF activity and VTE | 121 |
| Cancer | PPP | Levels of EV TF activity were increased in patients with cancer compared with healthy controls | 122 |
| COVID-19 | PPP | Levels of EV TF activity were increased in patients with COVID-19 compared with controls, and were associated with disease severity and mortality | 110 |
| COVID-19 | PFP | Levels of EV TF activity were increased in patients with severe COVID-19 and were associated with an increased thrombotic risk | 16 |
| COVID-19 and sepsis | PPP | Levels of EV TF activity were higher in ICU patients with COVID-19 than in patients with sepsis | 123 |
| Sepsis | PPP | Levels of EV TF activity were higher in patients with septic DIC than in healthy controls | 124 |
| Leukemia | PFP | Levels of EV TF activity were increased in patients with leukemia compared with controls | 125 |
| Prostate cancer | PPP | Levels of EV TF activity were increased in patients with cancer with DIC compared with patients with cancer without DIC | 126 |
| Lung cancer | PFP | Levels of EV TF activity were increased in patients with cancer compared with healthy controls. | 127 |
| COVID-19 | PFP | Levels of EV TF activity were higher in patients with COVID-19 than in healthy controls | 128 |
| COVID-19 | PFP | Levels of EV TF activity were higher in small EVs than in large EVs from patients with COVID-19 | 80 |
| Sepsis, pancreatic cancer, and COVID-19 | PFP and PPP | Levels of EV TF activity of small or large EVs were different depending on the disease | 129 |
| Sepsis | PPP | Levels of EV TF activity were increased in patients with sepsis with DIC compared with patients with sepsis without DIC. Levels of EV TF activity were associated with inflammatory markers and DIC score | 130 |
| Leukemia | PPP | Levels of EV TF activity were increased in patients with leukemia compared with controls, and were associated with risk of bleeding | 131 |
DIC, disseminated intravascular coagulation; HCPS, hantavirus cardiopulmonary syndrome; HFRS, hemorrhagic fever with renal syndrome; ICU, intensive care unit; PFP, platelet-free plasma; PPP, platelet-poor plasma; VTE, venous thromboembolism.